Pivotal S.L.
20
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
5 terminated/withdrawn out of 20 trials
64.3%
-22.2% vs industry average
15%
3 trials in Phase 3/4
33%
3 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
Role: collaborator
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Role: collaborator
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Role: collaborator
Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma
Role: collaborator
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Role: collaborator
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
Role: collaborator
FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
Role: collaborator
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
Role: collaborator
Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer
Role: collaborator
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
Role: collaborator
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
Role: collaborator
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Role: collaborator
Paclitaxel and TAK-228 in Urothelial Carcinoma
Role: collaborator
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
Role: collaborator
Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer
Role: collaborator
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
Role: collaborator
A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain
Role: collaborator
Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already Treated With Rotigotine
Role: collaborator
Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer
Role: collaborator
Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk
Role: collaborator
All 20 trials loaded